Skip to content

Avance clinical client news: XWPharma initiates first-in-human studies of XW10508, in development for fast-acting relief of treatment-resistant depression and chronic pain

By Gold Cross - October 20, 2021

This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

, , , ,

PATY 2025: Nominations now open!

Gold Cross | March 3, 2025
, ,

Free Flu Vaccinations for Queenslanders about to begin

Gold Cross | February 28, 2025
, , ,

Three weeks to go: Final preparations underway for APP2025

Gold Cross | February 27, 2025
Pharmacist Only
, , ,

Get ready for APP2025’s ‘Country Hoedown’ Street Party!

Gold Cross | February 25, 2025
BD Rowa automation gives you back 6 hours in your day

Latest Posts

PATY 2025: Nominations now open!
Gold Cross | March 3, 2025
Care Connect celebrates 30 years of care
Gold Cross | February 28, 2025
Free Flu Vaccinations for Queenslanders about to begin
Gold Cross | February 28, 2025

Featured Posts

GOLD CROSS endorses Team Medical®
Gold Cross | February 18, 2025
College training supports new Australian Government women’s health initiative
Gold Cross | February 10, 2025
Professor Anna Peeters appointed VicHealth CEO
Gold Cross | February 4, 2025

Tags

Scroll To Top